Printer Friendly

PFIZER INC - Research Update.

  New Lipitor Study Demonstrates That Intensive LDL Cholesterol Lowering in
     Heart Disease Patients Can Reduce Cardiovascular Events, Pfizer Says

    DALLAS, Nov. 15 -- Patients who had a previous heart attack and took
Pfizer Inc's cholesterol-lowering medicine Lipitor (atorvastatin calcium) to
further lower their LDL or "bad" cholesterol levels had significantly fewer
cardiovascular events including heart attacks, strokes or revascularization
procedures compared to patients taking Zocor (simvastatin).  Results of the
Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL)
study were presented today at the annual meeting of the American Heart
Association.  IDEAL is also published in this week's edition of the Journal of
the American Medical Association.
    There was an 11 percent reduction in major coronary events in Lipitor
patients compared to Zocor patients.  This difference did not reach
statistical significance (p = .07).  However, patients taking Lipitor
experienced a significant 17 percent reduction in non-fatal heart attacks and
a significant 13 percent reduction in major cardiovascular events compared to
patients taking Zocor.  Major cardiovascular events include heart disease-
related death, heart attack, cardiac arrest, and stroke.  Major coronary
events consist of major cardiovascular events other than stroke.  There were
no significant differences in adverse events, including serious adverse
events, between patients taking Lipitor and Zocor.
    According to the World Health Organization (WHO), cardiovascular disease
is the world's leading health threat, accounting for 16.7 million deaths
worldwide.  In the United States, over 60 million Americans are affected by
cardiovascular disease and more than one million die of it annually.  The
burden on society, between the need for care and lost wages and work days, is
considerable.
    In the five-year study, 8,888 patients with an average age of 62 who had a
previous heart attack, received either Lipitor (80 mg) or the most commonly
prescribed doses of Zocor (20 mg to 40 mg) to determine whether more intensive
lowering of LDL-cholesterol would provide additional cardiovascular benefits.
Unlike prior statin trials, the majority of patients in IDEAL were already
being treated with statins, beta-blockers, and aspirin prior to entering the
study.
    "The majority of IDEAL patients were taking multiple therapies to lower
their cardiovascular risk prior to entering the trial," said Dr. Terje
Pedersen, head of the Centre for Preventive Medicine at Ulleval University
Hospital, Oslo Norway, and the lead investigator for IDEAL.  "These results
show us that intensive lipid lowering therapy with Lipitor can significantly
reduce a patient's likelihood of experiencing another devastating event such
as a heart attack or stroke, or the need for bypass surgery compared to
patients taking standard Zocor therapy," said Dr. Terje Pedersen.
    Dr. Pedersen was also the lead investigator in the landmark Scandinavian
Simvastatin Survival Study (4S) trial involving Zocor which was the first
statin trial to show mortality benefits of statins.  Building on 4S, IDEAL
shows that reductions in cardiovascular events with Lipitor provide benefits
over and above the most commonly prescribed doses of Zocor (20 mg and
40 mg).The average LDL-cholesterol levels of participants entering the study
was 122 mg/dL.  Recent updated guidelines call for more aggressive LDL
lowering to levels of less than 100 mg/dL in CHD patients.  With intensive
Lipitor therapy, patients were able to lower their LDL-cholesterol levels even
further to an average of 81 mg/dL.  This was significantly lower than patients
taking Zocor, who had an average LDL-cholesterol level of 104 mg/dL.
    "IDEAL results build upon the previous evidence shown in the TNT and
PROVE-IT clinical trials that Lipitor's intensive lipid lowering can
effectively and safely provide patients with cardiovascular benefits that are
over and above other treatments," said Dr. Joseph Feczko, Pfizer's chief
medical officer.
    Since the introduction of Lipitor nearly nine years ago, its safety and
effectiveness have been supported through an extensive clinical trial program,
the Atorvastatin Landmark Program, with more than 400 ongoing and completed
trials involving more than 80,000 patients.  Lipitor is the most-prescribed
cholesterol-lowering therapy in the world with more than 100 million patient
years of experience.

SOURCE  Pfizer Inc
    -0-                             11/15/2005
    /CONTACT:  Vanessa Aristide for Pfizer Inc, +1-917-697-0481 on-site,
+1-212-733-3784 office/
    /Photo:  A free corporate logo to accompany this story is available immediately via Wieck
Photo Database to any media with telephoto receiver or electronic darkroom, PC or Macintosh,
that can accept overhead transmissions.  To retrieve a logo, please call 972-392-0888/
    /Web site:  http://www.pfizer.com /
    (PFE)









END
COPYRIGHT 2005 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire UK Disclose
Date:Nov 15, 2005
Words:726
Previous Article:PFIZER INC - Research Update.
Next Article:ARC RISK MANAGEMENT GROUP PLC - Interim Results.
Topics:


Related Articles
PFIZER INC - Research Update.
PFIZER INC - Research Update.
PFIZER INC - Research Update.
PFIZER INC - Research Update.
PFIZER INC - Research Update.
PFIZER INC - Research Update.
PFIZER INC - Research Update.
PFIZER INC - Research Update.
PFIZER INC - Research Update.
PFIZER INC - Research Update.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters